Poor Sleep
Sanofi India Limited and Cipla Limited have announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium®, a leading brand in the anti-epileptic medication category.
While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.
Union health minister JP Nadda on Saturday said India was at an "exciting juncture" in…
Paras Health has launched Paras Medi Clinic, a community-focused healthcare initiative and Gurugram’s neighbourhood clinic…
In a unique case of showing spirit of Raksha Bandhan, a 24-year-old man has saved…
The national capital reported 138 H1N1 cases in the last 24 hours, taking the cumulative…
The Central Government has imposed restrictions on the manufacture, sale, and distribution of all fixed-dose…
Addressing the 2nd ICC Medical Education Forum, organised by the Indian Chamber of Commerce (ICC) in association…